These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 21437222)

  • 1. Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives.
    Motta G; Cea M; Moran E; Carbone F; Augusti V; Patrone F; Nencioni A
    Clin Dev Immunol; 2010; 2010():428253. PubMed ID: 21437222
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma.
    Motta G; Cea M; Carbone F; Augusti V; Moran E; Patrone F; Nencioni A
    J BUON; 2011; 16(1):9-15. PubMed ID: 21674844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Monoclonal antibody immunotherapy for malignant non-Hodgkin's lymphoma].
    Jourdan E; Richard B
    Presse Med; 2000 Apr; 29(13):717-21. PubMed ID: 10797826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A molecular perspective on rituximab: A monoclonal antibody for B cell non Hodgkin lymphoma and other affections.
    Seyfizadeh N; Seyfizadeh N; Hasenkamp J; Huerta-Yepez S
    Crit Rev Oncol Hematol; 2016 Jan; 97():275-90. PubMed ID: 26443686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab immunotherapy for non-Hodgkin's lymphoma.
    White CA
    Cancer Biother Radiopharm; 1999 Aug; 14(4):241-50. PubMed ID: 10850310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced efficacy of gemcitabine in combination with anti-CD20 monoclonal antibody against CD20+ non-Hodgkin's lymphoma cell lines in vitro and in scid mice.
    Smith MR; Joshi I; Jin F; Obasaju C
    BMC Cancer; 2005 Aug; 5():103. PubMed ID: 16109167
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New developments in immunotherapy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Ruan J; Coleman M
    Curr Oncol Rep; 2005 Sep; 7(5):364-71. PubMed ID: 16091197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Auto-immune manifestations in Non-Hodgkin's lymphoma].
    Jardin F; Lévesque H; Tilly H
    Rev Med Interne; 2005 Jul; 26(7):557-71. PubMed ID: 15996570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel antibodies in the treatment of non-Hodgkin's lymphoma.
    Bhat SA; Czuczman MS
    Neth J Med; 2009 Sep; 67(8):311-21. PubMed ID: 19767657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transformation of Hodgkin's disease to high-grade B-cell lymphoma: remission after Rituximab monotherapy.
    Kirchner EM; Ebsen M; Kirchner J; Theegarten D; Voigtmann R
    Ann Oncol; 2001 Aug; 12(8):1169-71. PubMed ID: 11583202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab: a new therapeutic monoclonal antibody for non-Hodgkin's lymphoma.
    Scott SD
    Cancer Pract; 1998; 6(3):195-7. PubMed ID: 9652253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies in the treatment of non-Hodgkin's lymphoma.
    Fanale MA; Younes A
    Drugs; 2007; 67(3):333-50. PubMed ID: 17335294
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituxan immunotherapy and zevalin radioimmunotherapy in the treatment of non-Hodgkin's lymphoma.
    White CA
    Curr Pharm Biotechnol; 2003 Aug; 4(4):221-38. PubMed ID: 14529425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
    Kriachok IA; Filonenko KS; Gubareva GO; Tytorenko IB; Novosad OI; Kadnikova TV; Aleksik OM; Martynchyk AV; Kushchevyĭ ÉV; Pastushenko IaV; Kutsenko LB
    Lik Sprava; 2011; (1-2):117-21. PubMed ID: 21954645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a novel humanized anti-CD20 antibody with potent anti-tumor activity against non-Hodgkin's lymphoma.
    Zhang H; Song L; Ye H; Hu L; Liang W; Liu D
    Cell Physiol Biochem; 2013; 32(3):645-54. PubMed ID: 24022075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What signals are generated by anti-CD20 antibody therapy?
    Bonavida B
    Curr Hematol Malig Rep; 2006 Dec; 1(4):205-13. PubMed ID: 20425315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphocyte subsets and viral load in patients with HIV-associated non-Hodgkin's lymphoma treated with anti-CD20 monoclonal antibody and chemotherapy.
    De Paoli P; Vaccher E; Tedeschi R; Caffau C; Zanussi S; Bortolin MT; Crepaldi C; Spina M; Tirelli U
    Cancer Immunol Immunother; 2001 May; 50(3):157-62. PubMed ID: 11419183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
    Marcus R; Hagenbeek A
    Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma.
    Piro LD; White CA; Grillo-López AJ; Janakiraman N; Saven A; Beck TM; Varns C; Shuey S; Czuczman M; Lynch JW; Kolitz JE; Jain V
    Ann Oncol; 1999 Jun; 10(6):655-61. PubMed ID: 10442187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab in indolent lymphomas.
    Sousou T; Friedberg J
    Semin Hematol; 2010 Apr; 47(2):133-42. PubMed ID: 20350660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.